Report on Psychedelics Report on Psychedelics

In the Research Briefing:

- Flashbacks are common in psychedelic research but participants don't seem to mind
- LSD influences creativity, breaking down thought patterns and relocating them toward the new
- Psychedelics and society; thought on the past, present and future

In the Research Briefing:

- Ketamine effective in abstaining from alcohol for up to 6 months later
- Real-world data provides further evidence ketamine therapy is effective for depression
- But a large study finds ketamine not to be effective for PTSD in service members

In This Industry Briefing:
-Canada approves psychedelics for the SAP.
-Lexston's psychedelic journey.
-Nucleus, the data driven solution?
-Cannabis Vs. Psychedelics, the early days.
-Otsuka makes an investment into psychedelics.

In the Research Briefing

- Psilocybin can be administered safely for up to six people simultaneously
- An Open Science approach toward MDMA synthesis
- Nitrous Oxide could be the next antidepressant

In the Report:
-New double blind study does not find benefits of microdosing
-The negative post-acute effects of MDMA appear to be absent in the clinical setting.

In This Briefing:

The last few weeks have been a bit light on the side of psychedelic news. Whether it is because we are coming to the end of 2021 or for other reasons. Sometimes, a light week or 2 is a good thing, maybe the industry needs a bit of a news break.